Recombinant EPH Receptor A3 antibody

Catalog No. ABIN7543438

This anti-EPH Receptor A3 antibody is a Mouse Monoclonal antibody detecting EPH Receptor A3 in WB, ELISA, FACS, IF, IP, in vivo and SPR. Suitable for Human.

Quick Overview for Recombinant EPH Receptor A3 antibody (ABIN7543438)

Target: EPH Receptor A3 (EPHA3)

Antibody Type: Recombinant Antibody

Reactivity: Human

Host: Mouse

Clonality: Monoclonal

Conjugate: This EPH Receptor A3 antibody is un-conjugated

Application: Western Blotting (WB), ELISA, Flow Cytometry (FACS), Immunofluorescence (IF), Immunoprecipitation (IP), In vivo Studies (in vivo), Surface Plasmon Resonance (SPR)

Clone: IIIA4

Product Details anti-EPH Receptor A3 Antibody

Purpose: Anti-EpHA3 [IIIA4], Mouse IgG1, kappa

Specificity: The antibody binds to the native EphA3 globular ephrin-binding domain. The antibody targets a site closely adjacent to the heterotetramerization site on the N-terminal of EPHA3's extracellular domain adjacent to the ligand-binding site and has a high affinity for EPHA3.

Cross-Reactivity: Mouse

Characteristics:

Original Species of Ab: Mouse

Original Format of Ab: IgG1

Purification: Protein A affinity purified

Immunogen: The original antibody was prepared by intraperitoneal immunization of a BALB/c mouse with LK63 cells.

Isotype: IgG1 kappa

Application Details

Application Notes: This antibody was used for detection of hek expressed on LK63 cells by flow cytometry. Hek antigen was immunoprecipitated using the antibody from 125I-labeled LK63 cell lysates (Boyd et al., 1992, PMID: 1737782). The specificity of the chimeric version of the antibody was confirmed by ELISA analysis (US8664365). In a LK63 xenograft model, administration of the antibody inhibited the tumor growth, decreasing the spreading from the bone marrow to the spleen and other organs and increases the latency of the disease. Similar effects were observed in LK63 EPHA3 knock down xenografts. Further, antibody treatment of a xenograft model using EPHA3-transfected Reh, showed reduction in the bone marrow engraftment and increases the latency of the disease (Charmsaz et al., 2016, PMID: 27922598). The antibody bound to the native EphA3 globular ephrin-binding domain with subnanomolar affinity (KD ~ 0.5 nM) (Smith et al., 2004, PMID: 14660665). The antibody specifically stained EphA3 in 95 % of human tumor tissues from a broad range of cancer types (Vail et al. 2014, PMID: 25125683). The humanized version of the antibody (KB004), was tested in a multi-center Phase 1/2 trial, in patients with EphA3-positive hematologic neoplasms, including Chronic Myelogenous Leukemia, Acute Myeloid Leukemia, Acute lymphoblastic leukemia, Myelodysplastic Syndrome.

Restrictions: For Research Use only

Handling

Concentration: 1 mg/mL

Buffer: PBS with 0.02 % Proclin 300.

Preservative: ProClin

Precaution of Use: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: 4 °C,-20 °C

Storage Comment: Store at 4°C for up to 3 months. For longer storage, aliquot and store at -20°C.

Target Details for EPH Receptor A3

Target: EPH Receptor A3 (EPHA3)

Alternative Name: EpHA3

Background: Ephrin type-A receptor 3, EPH-like kinase 4, EK4, hEK4, HEK, Human embryo kinase, Tyrosine-protein kinase TYRO4, Tyrosine-protein kinase receptor ETK1, Eph-like tyrosine kinase 1, III.A4

UniProt: P29320

Pathways: RTK Signaling, Regulation of Cell Size